[{"address1": "700 Saginaw Drive", "city": "Redwood City", "state": "CA", "zip": "94063", "country": "United States", "phone": "650 481 6801", "website": "https://www.revmed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.", "fullTimeEmployees": 809, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mark A. Goldsmith M.D., Ph.D.", "age": 62, "title": "CEO, President & Chairman", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1347967, "exercisedValue": 10163472, "unexercisedValue": 51843852}, {"maxAge": 1, "name": "Mr. Jack  Anders", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 725633, "exercisedValue": 849639, "unexercisedValue": 2896538}, {"maxAge": 1, "name": "Ms. Margaret A. Horn J.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 897933, "exercisedValue": 3021392, "unexercisedValue": 16625696}, {"maxAge": 1, "name": "Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.", "age": 63, "title": "President of Research & Development", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 951933, "exercisedValue": 4257259, "unexercisedValue": 11511893}, {"maxAge": 1, "name": "Ms. Xiaolin  Wang", "age": 54, "title": "Executive Vice President of Development", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 701200, "exercisedValue": 0, "unexercisedValue": 13540803}, {"maxAge": 1, "name": "Dr. Martin D. Burke M.D., Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Fischbach Ph.D.", "age": 43, "title": "Academic Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevan M. Shokat Ph.D.", "title": "Academic Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Walter  Reiher Ph.D.", "title": "Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jan  Smith Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 75.96, "open": 77.56, "dayLow": 76.45, "dayHigh": 79.1, "regularMarketPreviousClose": 75.96, "regularMarketOpen": 77.56, "regularMarketDayLow": 76.45, "regularMarketDayHigh": 79.1, "payoutRatio": 0.0, "beta": 0.959, "forwardPE": -12.559424, "volume": 6158381, "regularMarketVolume": 6158381, "averageVolume": 2364800, "averageVolume10days": 3104470, "averageDailyVolume10Day": 3104470, "bid": 70.72, "ask": 82.29, "bidSize": 2, "askSize": 2, "marketCap": 15229733888, "fiftyTwoWeekLow": 29.17, "fiftyTwoWeekHigh": 81.487, "allTimeHigh": 81.487, "allTimeLow": 14.08, "fiftyDayAverage": 66.1396, "twoHundredDayAverage": 45.863674, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 13713196032, "profitMargins": 0.0, "floatShares": 173985891, "sharesOutstanding": 193319805, "sharesShort": 16792419, "sharesShortPriorMonth": 18022242, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.086899996, "heldPercentInsiders": 0.01872, "heldPercentInstitutions": 1.02389, "shortRatio": 7.09, "shortPercentOfFloat": 0.0922, "impliedSharesOutstanding": 193319805, "bookValue": 8.418, "priceToBook": 9.358517, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -960977984, "trailingEps": -5.19, "forwardEps": -6.27258, "enterpriseToEbitda": -13.316, "52WeekChange": 0.79330754, "SandP52WeekChange": 0.14402747, "quoteType": "EQUITY", "currentPrice": 78.78, "targetHighPrice": 104.0, "targetLowPrice": 72.0, "targetMeanPrice": 83.26316, "targetMedianPrice": 80.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 19, "totalCash": 1931507968, "totalCashPerShare": 9.991, "ebitda": -1029836992, "totalDebt": 414969984, "quickRatio": 7.864, "currentRatio": 8.051, "debtToEquity": 25.986, "returnOnAssets": -0.32287, "returnOnEquity": -0.6076, "grossProfits": -880484992, "freeCashflow": -438248512, "operatingCashflow": -761793024, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "RVMD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "longName": "Revolution Medicines, Inc.", "shortName": "Revolution Medicines, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1581604200000, "postMarketChangePercent": -0.101550944, "postMarketPrice": 78.7, "postMarketChange": -0.08000183, "regularMarketChange": 2.82, "regularMarketDayRange": "76.45 - 79.1", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2364800, "fiftyTwoWeekLowChange": 49.61, "fiftyTwoWeekLowChangePercent": 1.70072, "fiftyTwoWeekRange": "29.17 - 81.487", "fiftyTwoWeekHighChange": -2.7070007, "fiftyTwoWeekHighChangePercent": -0.03322003, "fiftyTwoWeekChangePercent": 79.33076, "earningsTimestamp": 1762376400, "earningsTimestampStart": 1762376400, "earningsTimestampEnd": 1762376400, "earningsCallTimestampStart": 1762378200, "earningsCallTimestampEnd": 1762378200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -5.19, "epsForward": -6.27258, "epsCurrentYear": -5.54092, "priceEpsCurrentYear": -14.217855, "fiftyDayAverageChange": 12.640396, "fiftyDayAverageChangePercent": 0.1911169, "twoHundredDayAverageChange": 32.916325, "twoHundredDayAverageChangePercent": 0.7176992, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1766192350, "regularMarketTime": 1766178001, "exchange": "NMS", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.71248, "regularMarketPrice": 78.78, "messageBoardId": "finmb_283775412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "displayName": "Revolution Medicines", "trailingPegRatio": null, "__fetch_time": "2025-12-20"}]